At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 451 enrolled
Drug / intervention
Truvada +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
In Brief
A Phase 4 clinical trial evaluating Truvada and Drug level counseling at Weeks 8 and 13 for HIV. Completed, enrolled 451 participants across 3 sites in 2 countries.
Detailed Summary
To assess the acceptance rate, adherence, acceptability, and continuation of oral pre-exposure prophylaxis (PrEP) among young southern African women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesSouth Africa, Zimbabwe
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartOct 2016
Primary CompletionOct 2018
TodayJul 2026
First PostedApr 11, 2016
Enrollment StartOct 12, 2016
Primary CompletionOct 25, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago
Interventions
Truvadadrug
400 women who accept to initiate PrEP
Drug level counseling at Weeks 8 and 13behavioral
Women who are randomized to enhanced counselling will have adherence monitoring based on plasma TFV levels obtained 4 and 8 weeks after PrEP acceptance